Literature DB >> 747293

[Oral treatment of severe psoriasis with a new aromatic retinoid (Ro 10-9359) (author's transl)].

J J Guilhou, S Malbos, J Meynadier.   

Abstract

The aromatic retinoic acid derivative Ro 10-9359 was administered orally to 25 severe psoriatic patients (14 with generalized plaques, 7 erythrodermic, 4 pustular). The initial dose was 25 mg/20 kg body weight daily for 4 weeks; afterwards the same posology was given every other day during several months (Max : 18 months). Excellent results were obtained in 16 patients (64 p. 100) particularly in severe erythrodermic and pustular psoriasis. However, under follow-up therapy relapses sometimes occurred leading to temporary resumption of initial posology. The most important side effects are cheilitis, palmoplantar scaling with thinning of the skin, hyperhidrosis and diffuse hair loss. A slight increase of transaminases and of alkaline phosphatases was found in a few patients. The Ro 10-9359 compound is a very useful new therapy of severe psoriasis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 747293

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  2 in total

Review 1.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

2.  Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359).

Authors:  A L Claudy; Y Delomier; C Hermier
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.